Breaking News Instant updates and real-time market news.

DB

Deutsche Bank

$8.03

0.32 (4.15%)

, SYMC

Symantec

$24.99

-0.26 (-1.03%)

09:16
07/08/19
07/08
09:16
07/08/19
09:16

Fly Intel: Pre-market Movers

HIGHER: Symantec (SYMC), up 5% after Bloomberg reports Broadcom (AVGO) has secured financing and identified cost savings for the acquisition of the company in an all-cash deal valued at more than $22B... Sangamo (SGMO), up 15% after announcing updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A... Orion Group (ORN), up 6% after B. Riley FBR analyst Alex Rygiel upgraded the stock to Buy from Neutral and raised his price target for the shares to $5 from $4. The recent weakness in the shares, partly due to deletion from the Russell 2000 index, was overdone, Rygiel tells investors... Sol-Gel (SLGL), up 6% after reporting the primary and secondary endpoints were achieved in Phase 3 trials of Epsolay. LOWER: Intra-Cellular (ITCI), down 16% after Study 401 of lumateperone did not its meet primary endpoint... Deutsche Bank (DB), down 5% after announcing it will reduce its workforce by 18,000 employees by 2022 as part of a broad restructuring plan. The bank also plans an exit of its Global Equities and a reduction in corporate and investment banking risk weighted assets... CannTrust (CTST), down 19% after receiving a compliance report from Health Canada notifying the company that its greenhouse facility in Pelham, Ontario is non-compliant with certain regulations... NetApp (NTAP), down 6% after Citi analyst Jim Suva downgraded shares to Sell from Neutral and lowered his price target for the shares to $55 from $67. The competitive landscape with Dell (DELL) against the slowing macro environment adds more pressure to the company, Suva tells investors... BNY Mellon (BK), down 3% after Morgan Stanley analyst Betsy Graseck double downgraded the stock to Underweight from Overweight and downgraded her industry view for large cap banks to In-Line from Attractive.

DB

Deutsche Bank

$8.03

0.32 (4.15%)

SYMC

Symantec

$24.99

-0.26 (-1.03%)

SGMO

Sangamo

$11.40

-0.21 (-1.81%)

ORN

Orion Group

$3.10

-0.08 (-2.52%)

SLGL

Sol-Gel Technologies

$9.20

(0.00%)

ITCI

Intra-Cellular

$13.44

0.58 (4.51%)

CTST

CannTrust

$4.93

-0.0899 (-1.79%)

NTAP

NetApp

$62.43

-0.06 (-0.10%)

BK

BNY Mellon

$44.53

-0.1 (-0.22%)

  • 08

    Jul

  • 09

    Jul

  • 17

    Jul

  • 25

    Jul

  • 31

    Jul

  • 06

    Aug

  • 27

    Sep

  • 13

    Nov

DB Deutsche Bank
$8.03

0.32 (4.15%)

05/20/19
05/20/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. American Airlines (AAL) downgraded to Underweight from Equal Weight at Morgan Stanley while Delta Air Lines (DAL) was downgraded to Equal Weight from Overweight. 2. Deutsche Bank (DB) downgraded to Sell from Neutral at UBS with the firm saying the bank is facing limited strategic options and its operating conditions are unlikely to improve in the near term amid intense competition. 3. Eaton Vance (EV) double downgraded to Underperform from Buy at BofA/Merrill with analyst Michael Carrier lowering estimates to reflect slower flow trends, a difficult product mix, and potential margin pressures ahead. 4. ProAssurance (PRA) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Christopher Campbell saying the stock has rallied 9% since the company's "disappointing" Q1 results. 5. Clorox (CLX) downgraded to Hold from Buy at Argus with analyst John Staszak citing the company's revenue deceleration reported in Q3 to "just 2%" as well as its near-term growth outlook cut to 2%-3% from 2%-4%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/08/19
RBCM
07/08/19
NO CHANGE
RBCM
Underperform
Deutsche Bank business review 'more radical than expected', says RBC Capital
RBC Capital analyst Anke Reingen raised her price target on Deutsche Bank to EUR8 from EUR7.50, saying its transformation plan announced over the weekend is "more radical than expected" and could support its shares over the short term. The analyst maintained her Underperform rating however, noting that the bank's execution will be key, while also pointing to the company's pushed out projections for improvement in profitability.
05/20/19
UBSW
05/20/19
DOWNGRADE
UBSW
Sell
Deutsche Bank downgraded to Sell from Neutral at UBS
UBS downgraded Deutsche Bank to Sell from Neutral and lowered its price target for the shares to EUR 5.70 from EUR 7.80. The bank is facing limited strategic options and its operating conditions are unlikely to improve in the near term amid intense competition, UBS tells investors in a research note.
07/08/19
BOFA
07/08/19
NO CHANGE
BOFA
Underperform
BofA keeps Underperform rating on Deutsche Bank, says capital still an issue
After Deutsche Bank released its outline of its new plan to improve profitability, BofA Merrill Lynch analyst Andrew Stimpson said the cost ambitions are greater than he expected, but he believes capital will continue to be an issue as the bank decided to not raise equity. Also, preliminary Q2 underlying results missed consensus, noted Stimpson, who keeps an Underperform rating on Deutsche Bank shares with many details of the company's plan still outstanding.
SYMC Symantec
$24.99

-0.26 (-1.03%)

07/08/19
JEFF
07/08/19
NO CHANGE
Target $24
JEFF
Hold
Symantec sale well above $24 per share would be 'huge windfall,' says Jefferies
Jefferies analyst John DiFucci raised his price target for Symantec (SYMC) to $24 from $19 after Bloomberg reported last week that Broadcom (AVGO) is in advanced talks to acquire the company. There is some logic in Symantec as a takeout candidate, "though at what price is the primary question," DiFucci tells investors in a research note. Further, the analyst does not believe that Broadcom's acquisition of CA is a good compare to this potential transaction. DiFucci views the value of Symantec's potential future free cash flow at about $24 per share. Any sale at a "material premium" to $24 per share would be a "huge windfall" to shareholders, says the analyst.
07/05/19
RHCO
07/05/19
NO CHANGE
Target $307
RHCO
Buy
Broadcom bias higher on Symantec speculation, says SunTrust
SunTrust analyst William Stein kept his Buy rating and $307 price target on Broadcom (AVGO) but says his bias is turning higher on the company's valuation and consensus expectations following this week's press speculation regarding its interest in Symantec (SYMC). The analyst contends that the dip in the Broadcom stock price is comparable to last year's downturn when the company announced a deal to acquire CA Technologies and should also be bought, since the shares recovered quickly as the assets "become a relatively better performing part" of the company's business this year. Stein is also positive on Broadcom's "outstanding historical track record of value creation" from its investing decisions and expects its management to continue to make "intelligent capital allocation decisions."
07/05/19
MSCO
07/05/19
NO CHANGE
Target $250
MSCO
Equal Weight
Broadcom reported deal talks likely to raise questions, says Morgan Stanley
After Bloomberg and the Financial Times reported that Broadcom (AVGO) is in advanced talks to buy Symantec (SYMC), Morgan Stanley analyst Craig Hettenbach said he thinks such a potential deal would be less surprising than the company's prior acquisition of CA, but there will likely be many questions about it given the deterioration in Symantec's business. He estimates such a potential deal could be approximately 10% accretive at a typical M&A premium and with a 10% reduction in operating expenses. Given that he thinks questions about Broadcom's strategy could linger, Hettenbach keeps an Equal Weight rating on the shares.
07/03/19
OPCO
07/03/19
NO CHANGE
OPCO
Perform
Oppenheimer sees Broadcom growing software focus as positive for Symantec
Oppenheimer analyst Shaul Eyal notes that both Bloomberg and the Financial Times are speculating that Broadcom (AVGO) could be acquiring Symantec (SYMC) for over $15B. The analyst sees Symantec's enterprise business struggling to firmly reestablish itself, Consumer business sustaining solid performance, and stable cash flows as potentially supporting the rationale for a transaction. Further, Eyal believes Broadcom's growing software focus could yield a positive outcome to Symantec's shareholders. The analyst has a Perform rating on Symantec's stock.
SGMO Sangamo
$11.40

-0.21 (-1.81%)

02/08/19
JEFF
02/08/19
NO CHANGE
Target $23
JEFF
Buy
Jefferies sees opportunity in Sangamo after selloff, drops target to $23
Jefferies analyst Maury Raycroft says his Buy thesis on Sangamo Therapeutics is unchanged following yesterday's update. The analyst lowered his price target for the shares to $23 from $26 and maintains a Buy rating. Sangamo demonstrated successful in vivo editing, Raycroft tells investors in a research note. The analyst has confidence in the company's update, noting Sangamo was able to detect an albumin-IDS mRNA transcript in a liver biopsy aspirate that extracted around 100,000-300,000 cells for analysis. Further, concern about patient six and the transaminitis is likely an overreaction as liver enzyme elevation is consistent across gene therapy programs, adds the analyst. Raycroft sees opportunity in Sangamo shares following yesterday's selloff.
02/07/19
WELS
02/07/19
NO CHANGE
Target $24
WELS
Outperform
Wells Fargo says buy Sangamo on today's 'overdone' selloff
Wells Fargo analyst Jim Birchenough lowered his price target for Sangamo Therapeutics to $24 from $39 following today's update for in-vivo gene editing in mucopolysaccharidosis type I and II. While overall results are disappointing in terms of markers of sustainable efficacy and suggest further optimization required of gene editing efficiency and delivery, individual patient validation with significant iduronate-2-sulfatase enzyme production in one of two high dose MPSII patients and evidence of enzyme production in MPSI is encouraging, Birchenough tells investors in an intraday research note titled "Over Reaction To In-Vivo Gene Editing Update." The analyst believes Sangamo shares are "oversold" on today's news and recommends buying on the weakness. He maintains an Outperform rating on the name. Sangamo shares in in afternoon trading are down 36%, or $4.28, to $7.74.
02/08/19
GSCO
02/08/19
NO CHANGE
Target $21
GSCO
Buy
Goldman says Orchard track record stands out amid disappointments in gene space
Goldman Sachs analyst Graig Suvannavejh noted that February 7 was "a day of disappointment" in the gene therapy and gene editing space, as Solid Biosciences (SLDB) and Sangamo (SGMO) both reported clinical efficacy data that missed investor expectations and "perhaps also raised concerns about the long-term promise of gene-based approaches." Within this context, he pointed out that he believes Orchard Therapeutics (ORTX) has "the most robust clinical experience in gene therapy, with over 150 patients treated across multiple product candidates and indications." The analyst, who expects new clinical data for Orchard candidates OTL-101 and OTL-102 to be presented later this month to re-affirm his confidence, reiterated his Buy rating and $21 price target on Orchard shares.
04/02/19
WELS
04/02/19
NO CHANGE
Target $34
WELS
Outperform
Sangamo price target raised to $34 from $24 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Sangamo Therapeutics to $34 from $24 following this morning's clinical update on the company's gene therapy, gene editing and cell therapy pipeline. The stock in morning trading is up 35%, or $3.35, to $12.88. The update was better than expected, particularly for hemophilia gene therapy and beta thalassemia ex vivo gene editing, Birchenough tells investors in a research note. The analyst is "encouraged" by Sangamo's progress against the higher technical hurdle of in vivo genome editing. He believes direct evidence of genome editing, "strong" fetal hemoglobin response and early signs of transfusion independence bode well for ultimate success and should translate into improved likelihood of success in the larger opportunity of sickle cell disease. The analyst reiterates an Outperform rating on Sangamo Therapeutics.
ORN Orion Group
$3.10

-0.08 (-2.52%)

07/08/19
RILY
07/08/19
UPGRADE
Target $5
RILY
Buy
B. Riley FBR upgrades Orion Group to Buy, says pullback overdone
B. Riley FBR analyst Alex Rygiel upgraded Orion Group to Buy from Neutral and raised his price target for the shares to $5 from $4. The recent weakness in the shares, partly due to deletion from the Russell 2000 index, was overdone, Rygiel tells investors in a research note. He believes Orion's turnaround is in process, "strong" new awards in Q2 provides the foundation for a financial rebound, and that the shares are attractively valued at current levels.
07/08/19
RILY
07/08/19
UPGRADE
Target $5
RILY
Buy
Orion Group upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Alex Rygiel upgraded Orion Group to Buy from Neutral and raised his price target for the shares to $5 from $4.
10/19/18
RILY
10/19/18
DOWNGRADE
Target $7
RILY
Neutral
Orion Group downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Alex Rygiel downgraded Orion Group to Neutral and lowered his price target for the shares to $7 from $11 after the company's preliminary Q3 results missed expectations.
SLGL Sol-Gel Technologies
$9.20

(0.00%)

07/16/18
HCWC
07/16/18
INITIATION
Target $21
HCWC
Buy
Sol-Gel Technologies initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Sol-Gel Technologies with a Buy rating and $21 price target. The analyst believes peak Twin sales may approach $260M by 2028 while while Vered might reach peak sales of $785M in 2027.
ITCI Intra-Cellular
$13.44

0.58 (4.51%)

12/12/18
ADAM
12/12/18
NO CHANGE
Target $31
ADAM
Buy
Intra-Cellular's NDA acceptance puts some investors fears to bed, says Canaccord
Canaccord analyst Sumant Kulkarni maintained a Buy rating and $31 price target on Intra-Cellular after the FDA accepted its new drug application for lumateperone for schizophrenia, and granted a PDUFA date of September 27, 2019, which paves the way for the company to potentially have a product on the market next year. In a research note to investors, Kulkarni says the NDA acceptance was expected, but the announcement puts some investor fears to bed. If approved, the analyst believes lumateperone could present a meaningful product for the treatment of schizophrenia given its relatively benign safety/side effect profile vs. the current standard of care.
12/12/18
12/12/18
NO CHANGE
Target $37

Outperform
Intra-Cellular price target raised to $37 from $35 at RBC Capital
As previously reported, RBC Capital analyst Brian Abrahams raised Intra-Cellular's price target to $37 from $35, saying the FDA NDA acceptance "meaningfully" de-risked the potential for lead drug lumateperone in its most advanced indication, schizophrenia. The analyst also believe shares significantly undervalue lumateperone's potential across neuropsych indications, with potential for bipolar depression data and schizophrenia approval to catalyze upside in 2019. He keeps an Outperform rating on the stock.
05/23/19
CANT
05/23/19
NO CHANGE
Target $29
CANT
Overweight
Intra-Cellular price target raised to $29 from $26 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Intra-Cellular to $29 from $26 and reiterates an Overweight rating on the shares. Following due diligence, the analyst sees reduced regulatory and commercial risk for lumateperone in its lead indication schizophrenia.
11/13/18
LEER
11/13/18
INITIATION
Target $27
LEER
Outperform
Intra-Cellular initiated with an Outperform at Leerink
Leerink analyst Marc Goodman started Intra-Cellular with an Outperform and $27 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Intra-Cellular, Goodman believes that lumateperone should get approved for the treatment of schizophrenia and drive about $400M of peak sales for this indication in 2029.
CTST CannTrust
$4.93

-0.0899 (-1.79%)

07/03/19
SBSH
07/03/19
NO CHANGE
Target $7
SBSH
Buy
Citi sees a 'lot of upside' in CannTrust shares, starts with Buy rating
Citi analyst Wendy Nicholson initiated coverage of CannTrust Holdings with a Buy rating and $7 price target. The stock closed yesterday down 15c to $4.97. CannTrust is one of the largest licensed producers of cannabis in Canada, and is well positioned to compete in the "rapidly-evolving" global cannabis market, Nicholson tells investors in a search note titled "Not a Lot of Visibility, but We See a Lot of Upside." Through its "state-of-the-art" cultivation and growing operations, CannTrust is focused on producing consistently high-quality and increasingly low-cost cannabis, explains the analyst. With its revenues "growing strongly," but path to profitability "less clear," Nicholson values the stock on a sales multiple. She expects CannTrust's sales to nearly triple in 2019 and nearly double again in 2020.
05/24/19
05/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Perform at Oppenheimer. 2. CannTrust (CTST) initiated with a Buy at BofA/Merrill. 3. Inseego (INSG) initiated with an Outperform at Cowen. 4. Falcon Minerals (FLMN) initiated with an Outperform at Baird. 5. Aphria (APHA) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/30/19
BMOC
05/30/19
UPGRADE
Target $11
BMOC
Outperform
CannTrust upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Tamy Chen upgraded CannTrust (CTST) to Outperform and raised his price target on the stock to $11 from $10. The analyst cites the company's ramp of its Phase 2 greenhouse development observed in his recent visit, saying the site is nearing a full capacity of 50k kg per year ahead of his prior expectations. Chen notes that CannTrust's run rate is third only to Canopy (CGC) and Aurora (ACB), even though it trades at a "notable discount."
07/03/19
SBSH
07/03/19
INITIATION
Target $7
SBSH
Buy
CannTrust initiated with a Buy at Citi
Citi analyst Wendy Nicholson started CannTrust Holdings with a Buy rating and $7 price target. The analyst says that while the company's path to profitability is "less clear," its revenues are growing "strongly." As a result, she values CannTrust on a sales multiple and sees "lots of upside" in the shares.
NTAP NetApp
$62.43

-0.06 (-0.10%)

06/06/19
EVER
06/06/19
INITIATION
Target $65
EVER
In Line
NetApp's positives offset by macro issues, competition, says Evercore ISI
Evercore ISI analyst Amit Daryanani started NetApp (NTAP) with an In Line rating and $65 price target, reflecting a balance between positive and negative dynamics. In a research note to investors, Daryanani says NetApp's cloud data services provides a unique, sticky, recurring revenue potential with fiscal 2021 exit at $600M ARR, but offsetting the positives are macro issues that slow down the pace of revenue growth especially in the new verticals, as well as competition as Dell (DELL) becomes a more stable and viable competitor.
06/06/19
PIPR
06/06/19
NO CHANGE
PIPR
Piper updates top picks across Security, Storage and Networking
Piper Jaffray analyst Andrew Nowinski updated his top picks across the Security, Storage and Networking sectors. The analyst's top picks in Security are Proofpoint (PFPT), SailPoint (SAIL) and Zscaler (ZS). His top picks in Storage are Pure Storage (PSTG) and NetApp (NTAP). And his top picks in Networking are Akamai (AKAM) and Arista Networks (ANET).
06/05/19
EVER
06/05/19
INITIATION
Target $65
EVER
In Line
NetApp initiated with an In Line at Evercore ISI
Evercore ISI started NetApp with an In Line rating and $65 price target.
07/08/19
SBSH
07/08/19
DOWNGRADE
Target $55
SBSH
Sell
NetApp downgraded to Sell from Neutral at Citi
Citi analyst Jim Suva downgraded NetApp (NTAP) to Sell from Neutral and lowered his price target for the shares to $55 from $67. The competitive landscape with Dell (DELL) against the slowing macro environment adds more pressure to the company, Suva tells investors in a research note. The analyst says he's picked up recent competitive pressures against NetApp by Dell, Hewlett-Packard Enterprise (HPE), Pure Storage (PSTG) and Nutanix (NTNX). As a result, Suva expects share and margin pressures for NetApp.
BK BNY Mellon
$44.53

-0.1 (-0.22%)

07/08/19
MSCO
07/08/19
DOWNGRADE
MSCO
Underweight
Morgan Stanley cuts large cap banks view, double downgrades State Street, BNY
As previously reported, Morgan Stanley analyst Betsy Graseck double downgraded State Street (STT) and BNY Mellon (BK), each to Underweight from Overweight, and downgraded her industry view for large cap banks to In-Line from Attractive. The group is up 23% year-to-date, but the next 6-18 months look tougher as global GDP is slowing, inflation expectations are dimming and the Fed is expected to cut rates in 2019 and 2020, which will make it "much harder for bank stocks to deliver positive surprises in operating leverage," Graseck tells investors. While she is not double downgrading the group to Cautious, because credit remains strong, Graseck sees trust banks as most exposed to the yield curve ahead of what she foresees as "18 months of rate cuts," the analyst added. She lowered her price targets on a number of large cap banks and cut her target on State Street to $55 from $69 while dropping her target for BNY to $41 from $50.
07/08/19
MSCO
07/08/19
DOWNGRADE
MSCO
Underweight
BNY Mellon downgraded to Underweight from Overweight at Morgan Stanley
Morgan Stanley analyst Betsy Graseck double downgraded BNY Mellon to Underweight from Overweight.
06/18/19
DBAB
06/18/19
DOWNGRADE
Target $44
DBAB
Hold
BNY Mellon downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Brian Bedell downgraded Charles Schwab to Hold from Buy and lowered his price target for the shares to $44 from $50. The analyst is downgrading some interest rate sensitive stocks in the Brokers and Asset Managers space ahead of the Q2 reporting season.
04/18/19
RBCM
04/18/19
NO CHANGE
Target $52
RBCM
Sector Perform
BNY Mellon price target lowered to $52 from $58 at RBC Capital
RBC Capital analyst Gerard Cassidy lowered his price target on BNY Mellon to $52 and kept his Sector Perform rating, saying the company hit an "air pocket" in Q1 as revenues underperformed expectations due to pricing pressure and negative core business trends. The analyst notes that BNY Mellon is "focused on optimizing profitability through organic growth" but the stock may continued trading at the lower end of its historical multiple range until there is an improvement in pricing, a more benign outlook for interest rates, and more consistent positive operating leverage.

TODAY'S FREE FLY STORIES

FTCH

Farfetch

$20.39

-0.13 (-0.63%)

17:28
07/16/19
07/16
17:28
07/16/19
17:28
Initiation
Farfetch initiated  »

Farfetch initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

  • 13

    Aug

HYRE

HyreCar

$3.44

0.21 (6.50%)

17:26
07/16/19
07/16
17:26
07/16/19
17:26
Syndicate
HyreCar files to sell 3.5M shares of common stock »

Northland Capital Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$8.19

-0.23 (-2.73%)

17:24
07/16/19
07/16
17:24
07/16/19
17:24
Hot Stocks
Breaking Hot Stocks news story on Mallinckrodt »

Mallinckrodt falls over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 09

    Sep

MNK

Mallinckrodt

$8.19

-0.23 (-2.73%)

17:23
07/16/19
07/16
17:23
07/16/19
17:23
Hot Stocks
Mallinckrodt halts Phase 2B trial investigating use of Acthar gel in ALS »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 09

    Sep

LNG

Cheniere Energy

$67.77

-0.66 (-0.96%)

17:22
07/16/19
07/16
17:22
07/16/19
17:22
Initiation
Cheniere Energy initiated  »

Cheniere Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSII

Cardiovascular Systems

$44.00

-1.9 (-4.14%)

17:20
07/16/19
07/16
17:20
07/16/19
17:20
Downgrade
Cardiovascular Systems rating change  »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

  • 09

    Sep

  • 12

    Sep

TELL

Tellurian

$7.68

-0.1 (-1.29%)

17:18
07/16/19
07/16
17:18
07/16/19
17:18
Downgrade
Tellurian rating change  »

Tellurian downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

GDDY

GoDaddy

$73.63

0.58 (0.79%)

17:05
07/16/19
07/16
17:05
07/16/19
17:05
Hot Stocks
GoDaddy Chief Accounting Officer Rebecca Morrow resigns »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 14

    Aug

NUS

Nu Skin

$45.50

1.44 (3.27%)

17:05
07/16/19
07/16
17:05
07/16/19
17:05
Hot Stocks
Breaking Hot Stocks news story on Nu Skin »

Nu Skin falls over 14% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUS

Nu Skin

$45.50

1.44 (3.27%)

17:05
07/16/19
07/16
17:05
07/16/19
17:05
Earnings
Nu Skin cuts FY19 EPS view to $3.20-$3.35 from $3.80-$4.05, consensus $3.95 »

Cuts FY19 revenue view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUS

Nu Skin

$45.50

1.44 (3.27%)

17:03
07/16/19
07/16
17:03
07/16/19
17:03
Earnings
Nu Skin cuts Q2 EPS view to 82c-84c from 91c-98c, consensus 94c »

Cuts Q2 revenue view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCEHY

Tencent

$0.00

(0.00%)

, ATVI

Activision Blizzard

$46.98

-0.67 (-1.41%)

16:58
07/16/19
07/16
16:58
07/16/19
16:58
Periodicals
Drake's esports team raises $35M, NY Post says »

According to a story from…

TCEHY

Tencent

$0.00

(0.00%)

ATVI

Activision Blizzard

$46.98

-0.67 (-1.41%)

NTES

NetEase

$259.36

3.01 (1.17%)

EA

Electronic Arts

$89.57

-2.65 (-2.87%)

NVDA

Nvidia

$167.06

-0.18 (-0.11%)

AMD

AMD

$33.82

-0.57 (-1.66%)

MSFT

Microsoft

$137.08

-1.86 (-1.34%)

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$117.49

0.47 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 18

    Jul

  • 19

    Jul

  • 30

    Jul

  • 30

    Jul

  • 05

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 14

    Aug

  • 15

    Aug

  • 05

    Sep

  • 13

    Nov

CSII

Cardiovascular Systems

$44.00

-1.9 (-4.14%)

16:57
07/16/19
07/16
16:57
07/16/19
16:57
Downgrade
Cardiovascular Systems rating change  »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

  • 09

    Sep

  • 12

    Sep

UAL

United Continental

$94.00

2.7 (2.96%)

16:54
07/16/19
07/16
16:54
07/16/19
16:54
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United Continental sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

UAL

United Continental

$94.00

2.7 (2.96%)

16:53
07/16/19
07/16
16:53
07/16/19
16:53
Hot Stocks
United Continental sees Q3 total mainline aircraft of 804 »

Sees Q3 total regional…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

UAL

United Continental

$94.00

2.7 (2.96%)

16:50
07/16/19
07/16
16:50
07/16/19
16:50
Hot Stocks
United Continental sees FY19 consolidated capacity growth 3%-4% y/y »

Sees FY19: Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

FARO

Faro Technologies

$46.95

-1.27 (-2.63%)

16:47
07/16/19
07/16
16:47
07/16/19
16:47
Hot Stocks
FARO names Allen Muhich CFO »

FARO announced that Allen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HWC

Hancock Whitney

$38.70

0.28 (0.73%)

16:47
07/16/19
07/16
16:47
07/16/19
16:47
Earnings
Hancock Whitney reports Q2 EPS $1.01, consensus $1.00 »

Reports Q2 NII $219.9M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 23

    Sep

UAL

United Continental

$94.00

2.7 (2.96%)

16:44
07/16/19
07/16
16:44
07/16/19
16:44
Hot Stocks
United Continental sees Q3 capacity growth 2%-3% y/y »

Sees Q3: Adjusted pre-tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

16:39
07/16/19
07/16
16:39
07/16/19
16:39
General news
API crude inventories for week of July 12 »

API reports that crude…

HOPE

Hope Bancorp

$13.96

0.2 (1.45%)

16:37
07/16/19
07/16
16:37
07/16/19
16:37
Earnings
Hope Bancorp reports Q2 EPS 34c, consensus 34c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

INO

Inovio

$3.00

0.05 (1.69%)

16:35
07/16/19
07/16
16:35
07/16/19
16:35
Hot Stocks
Breaking Hot Stocks news story on Inovio 

Inovio trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMRN

Immuron

$4.27

1.43 (50.35%)

16:32
07/16/19
07/16
16:32
07/16/19
16:32
Syndicate
Immuron files to sell American Depositary Shares, no amount given »

ThinkEquity, a division…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$115.10

1.23 (1.08%)

, GS

Goldman Sachs

$215.57

4.02 (1.90%)

16:32
07/16/19
07/16
16:32
07/16/19
16:32
On The Fly
Fly Intel: Wall Street's top stories for Tuesday »

The major averages were…

JPM

JPMorgan

$115.10

1.23 (1.08%)

GS

Goldman Sachs

$215.57

4.02 (1.90%)

JNJ

Johnson & Johnson

$132.46

-2.21 (-1.64%)

WFC

Wells Fargo

$45.30

-1.4 (-3.00%)

ARW

Arrow Electronics

$67.67

-1.15 (-1.67%)

TSLA

Tesla

$252.38

-1.03 (-0.41%)

APRN

Blue Apron

$10.33

2.68 (35.03%)

BYND

Beyond Meat

$172.50

5.9 (3.54%)

JBHT

J.B. Hunt

$97.76

5.26 (5.69%)

QTT

Qutoutiao

$4.31

-0.22 (-4.86%)

DPZ

Domino's Pizza

$246.55

-23.42 (-8.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 18

    Jul

  • 24

    Jul

  • 29

    Jul

  • 06

    Aug

  • 06

    Aug

  • 06

    Aug

  • 26

    Aug

  • 09

    Sep

  • 16

    Sep

  • 12

    Oct

  • 13

    Nov

PBYI

Puma Biotechnology

$10.78

-0.42 (-3.75%)

16:32
07/16/19
07/16
16:32
07/16/19
16:32
Hot Stocks
Knight says Health Canada approves NERLYNX for early-stage breast cancer »

Knight Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.